Contract Award

Physiomics PLC

31 August 2023

 

31 August 2023

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA that it expects to be completed over the next three months.  The project will involve pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage/ repair agents and follows on from previous projects commissioned by Merck KGaA.

Physiomics CEO, Dr Jim Millen, commented: "We are pleased that this longstanding client has once again chosen Physiomics as a partner for outsourced modelling. We look forward to the possibility of further projects with Merck during the current financial year."

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.  Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.  Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

END